Iron is the second most abundant metal on Earth after aluminium and is an essential element for all known forms of life. Numerous enzymes involved in DNA replication, repair and translation rely on iron, often in the form of iron-sulfur (Fe-S) clusters, for proper functioning in animals, plants and fungi, as well as in organisms from the two prokaryotic domains of life, Bacteria and Archea
1
. The biological activity of iron lies largely in its efficient electron transferring properties, enabling it to accept or donate electrons while switching between its ferrous bivalent (Fe(II), Fe 2+ ), ferric trivalent (Fe(III), Fe 3+ ) and its ferryl tetravalent (Fe(IV), Fe 4+ ) states, thereby functioning as a catalysing cofactor in various biochemical reactions 2 . In vertebrates, the second main role of iron involves the oxygen-binding characteristic of porphyrin-complexed iron, better known as haem, which is crucial for the oxygen-carrying capacity of haemoglobin and myoglobin.
Taking into account these vital functions of iron in human physiology, it is clear that systemic or cellular disorders in iron metabolism may have serious consequences. At the systemic level, haem incorporated in haemoglobin and myoglobin accounts for more than half of the approximately 4 g of iron present in the human body 3 . Moreover, the largest share of the total iron turnover is for haem production 3 . Consequently, an insufficient iron supply, unmet demand for iron or substantial loss of iron will lead to a shortage of haemoglobin, resulting in iron-deficiency anaemia 4 . Conversely, patients with red blood cell disorders such as β-thalassaemia suffer from iron-loading anaemia, which is associated with malformed red blood cells that have a reduced lifespan due to dysfunctional β-globin expression and reduced haemoglobin production 5 . In an attempt to compensate for the chronic anaemia, these individuals produce large numbers of erythroid progenitors. This high erythroid activity is accompanied by a greatly increased iron demand, which promotes iron absorption and in turn causes serious comorbidity resulting from iron overloading.
At the cellular level, the presence of intracellular iron has a strong impact on the cellular redox status, contributing to oxidative stress in individual cells. Reactive oxygen species (ROS), such as superoxide (O 2 − ) and hydrogen peroxide (H 2 O 2 ), which are formed by a single and double univalent reduction of molecular oxygen (O 2 ), respectively, are known to catalyse specific cellular redox reactions and are therefore involved in several signalling pathways. However, further reduction of relatively harmless H 2 O 2 results in the formation of hydroxyl radicals (OH • ) that are highly reactive, causing nonspecific oxidation and damage to nucleic acids, lipids and proteins 6 . Iron, as well as other metals, catalyses the formation of OH
• from other ROS by Fenton chemistry 7 , which involves the oxidation of Fe(II) to Fe(III) and electron transfer to H 2 O 2 . The presence of superoxide further assists this process by promoting the reduction of Fe(III) to form Fe(II) (and O 2 ) to complete the catalytic electron transport cycle of iron known as the Haber-Weiss reaction 8 .
As a consequence of its well-established roles in iron-deficiency anaemia and iron-loading anaemia, iron metabolism has historically remained within the scope of haematological pathologies. However, over the past decade, a range of ageing-related, non-haematological disorders has also been associated with deregulated iron homeostasis. In this Review, we discuss iron metabolism
Microcytic, hypochromic anaemia
Low systemic haemoglobin levels associated with a reduced haemoglobin concentration inside each red blood cell, making them small (microcytic) and pale (hypochromic). This condition is most commonly caused by iron deficiency, but is also found in patients with red blood cell disorders such as thalassaemia.
as a target for the development of new therapeutics or drug delivery strategies in these diseases. We provide a systematic overview of the iron regulatory pathways and its key players, as well as the major pathophysiologies associated with dysfunctional iron homeostasis. We then review some the most promising iron metabolism-targeted therapeutics in development, which could provide new therapeutic options for these often difficult-to-treat disorders.
Physiology of iron metabolism Systemic iron regulation: the hepcidin−ferroportin axis. Hepcidin is a peptide comprising 25 amino acids that is encoded by the HAMP gene and named for its high expression in the liver 9 . Hepcidin was originally thought to be a peptide with moderate antimicrobial activity 9, 10 , but it was soon recognized to be the master regulator of systemic iron metabolism 11 . Hepcidin regulates the systemic flux of iron by modulating the levels of ferroportin, the only known cellular exporter of unbound iron in vertebrates, on the cell surface 12 . By directly binding to the extracellular domain of ferroportin, hepcidin induces the endocytosis and degradation of this transmembrane protein, thereby preventing iron egress from the cell 13 . High levels of ferroportin are found in enterocytes in the duodenum (to transport absorbed iron), in hepatocytes (to transport stored iron) and in macrophages (to transport recycled iron), which together control systemic iron levels [14] [15] [16] . By reducing surface ferroportin, the expression of hepcidin limits the absorption, remobilization and recycling of iron, thereby reducing iron plasma levels (FIG. 1) .
With hepcidin as the central orchestrator, all major regulatory pathways of systemic iron homeostasis converge on HAMP transcription, mostly via SMAD signalling (FIG. 2) . As a result, alterations of or mutations in the genes encoding proteins that act within these pathways have been associated with various disorders, including primary and secondary forms of iron overload, and chronic anaemia. Consequently, these proteins, together with ferroportin, are some of the most interesting therapeutic targets that could be exploited for several disorders (TABLE 1) . Cellular iron regulation. Cellular iron trafficking can be separated into three processes: intake, utilization and efflux (FIG. 3; TABLE 2 ). There are four general pathways by which individual cells internalize iron. The most important pathway is centred on transferrin, an abundant plasma protein that acts as a natural chelating agent with two high-affinity binding sites for ferric iron 17 . Transferrin fulfils several crucial physiological roles that include the solubilization of relatively insoluble Fe(III), the prevention of iron-mediated redox toxicity and the systemic trafficking of iron. Although under normal circumstances, less than 0.1% of total body iron is bound by transferrin, the high turnover of transferrin ensures that each day 20-30 mg of iron is delivered to the bone marrow for erythropoiesis. Cellular internalization of transferrin-bound iron typically occurs after docking with the membrane-bound transferrin receptor 1 (TFR1), which has nanomolar affinity for iron-bound transferrin, but not for apotransferrin (that is, iron-free transferrin), at physiological pH 18 . The transferrin-TFR1 complex is internalized via clathrin-mediated endocytosis, and Fe(III) is liberated from transferrin as a result of a drop in pH to 5.5 within the vesicle. Subsequently, TFR1 and apotransferrin, which remain associated at this low pH, are recycled back to the cell surface, where the pH is physiological and apotransferrin is thus released 19 . In addition to the TFR-mediated uptake of transferrin, cells can also use an alternative, low-affinity route for transferrin internalization 20 . The second route by which cells can acquire iron is through the uptake of non-transferrin-bound iron (NTBI), which can be regarded as 'free iron'. Currently, three cellular membrane transporters are known to be involved in the uptake of NTBI: divalent metal-ion transporter 1 (DMT1) 21 , Zrt-and Irt-like protein 14 (ZIP14) 22 and, most recently, ZIP8 (REF. 23 ).
In 1997, DMT1 was identified as a key mammalian metal-ion transporter that is responsible for the intestinal iron absorption of cationic bivalent metals such as Fe(II), Cd(II), Co(II), Cu(II), Pb(II), Mn(II), Ni(II) and Zn(II) 21 . Around the same time, homozygous mutations in the gene encoding DMT1 (Slc11a2) was identified as the cause of the inheritable microcytic, hypochromic anaemia 24, 25 . This condition is found in mk/mk mice and Belgrade (b) rats, and was already known to be associated with an impaired intestinal uptake and erythroid utilization of iron 24, 25 . The critical role of DMT1 in the absorption of dietary nonhaem iron has recently been confirmed using intestinal Slc11a2-knockout mice 26 . In humans, homozygous or compound heterozygous mutations in the SLC11A2 gene have been associated with microcytic anaemia 27 . However, in contrast to the rodent models, patients with mutations in SLC11A2 are overloaded with iron rather than deficient. This effect is likely to be caused by a residual capacity for iron absorption, fulfilled either by the DMT1 mutant or by an alternative (haem) absorption pathway that is further stimulated by a regulatory feedback mechanism driven by the microcytic anaemia. The microcytic hypo chromic anaemia in these patients, and in the mk/mk mice and Belgrade (b) rats, is therefore primarily related to the other main role of DMT1: the transport of Fe(II) through the endosomal membrane. As demonstrated in mk/mk mice, DMT1 colocalizes with TFR1 in the endosome to mediate the cellular import of iron that is liberated from the transferrin-TFR1 complex. DMT1 dysfunction particularly 
Haemochromatosis
A family of hereditary diseases that are characterized by genetic mutations affecting an iron metabolism-regulating protein and resulting in excessive iron absorption. As there is no physiological mechanism for iron excretion, iron overload will eventually occur.
affects the developing red blood cells, as these cells require a substantial supply of iron and are heavily dependent on transferrin-TFR1-mediated import 28 . More recently, ZIP14 has been shown to fulfil an important role in the tissue accumulation of iron by NTBI. In genetic models of iron overloading in mice, ZIP14 deficiency reduced iron content in the liver and pancreas and provided some level of protection against hereditary haemochromatosis 29 . Each of the iron transporters only transports soluble Fe(II); therefore these transporters require enzymes with ferro reductive activity to reduce Fe(III) before internalization. Family members of cytochrome b561, the best known of which is DCYTB, which is expressed in the duodenum 30 , as well as six-transmembrane epithelial antigen of prostate (STEAP), which is found in erythroid progenitor cells 31 , have demonstrated such ferroreductive activity 32 . Recently, prion proteins present on the surface of neuronal cells have also been shown to possess ironreducing capacity; thus, prion proteins assist in the cellular uptake of NTBI in the brain 33, 34 . The third mechanism for iron internalization is the uptake of porphyrin-bound iron in the form of haemoglobin and haem. The scavenger receptor CD163 is almost exclusively expressed by macrophages and is specialized to take in haemoglobin in complex with the glycoprotein haptoglobin 35, 36 . Similarly, pro-low-density lipoprotein receptor-related protein 1 (LRP1; also known as CD91), orchestrates the uptake of haem that is in complex with the glycoprotein haemopexin 37 . Although LRP1 is considered to be a promiscuous receptor that recognizes other ligands, LRP1 is highly expressed by CD163-positive macrophages and may therefore be an essential route for the clearance of iron that was incorporated into haemoglobin and other haem-containing proteins. Haem-responsive gene 1 protein homologue (HRG1) 38 and feline leukaemia virus subgroup C receptor-related protein 2 (FLVCR2) 39 are also haemimporting proteins. Although their role in cellular iron trafficking needs to be further elucidated, it has been shown that HRG1 in particular is involved in the transport of haem across the lysosomal membrane upon internalization and degradation of erythrocytes and haemoglobin by macrophages 40 .
The fourth general pathway for iron internalization consists of the uptake of the iron-storage protein ferritin by receptors that include scavenger receptor class A member 5 (SCARA5) 41 and TFR1 (REF. 42) . A currently uncharacterized human ferritin receptor that could be related to TIM2, a well-characterized ferritin receptor in mice, might also be involved 43, 44 . Once inside the cell, iron can be utilized and stored. Mitoferrin 1 and 2 are specialized transporters that move iron into the mitochondria, where it assists with cellular respiration and is used for the synthesis of Fe-S clusters and haem 45 . Intracellular iron can be stored in two forms: stably incorporated into ferritin, an iron-sequestering protein that can contain up to 4,500 iron atoms 46 , or as active unbound species, known as the labile iron pool. Because an excess labile iron pool may cause oxidative stress-related toxicity, iron is generally stored as cytosolic ferritin, with the liver functioning as the primary organ for systemic iron storage. The labile iron pool is largely responsible for the regulation of cellular iron homeostasis through the iron regulatory protein-iron-responsive element system, which post-transcriptionally modulates the translation of mRNAs of several proteins that are involved in cellular iron trafficking, including DMT1, TFR1, ferritin and ferroportin 47, 48 . The export of iron from cells is almost exclusively managed by ferroportin (TABLE 1) . As a result, hepcidin regulates systemic iron uptake and mobilization by inducing the degradation of ferroportin, as discussed above. The multi-copper oxidases ceruloplasmin (in serum and astrocytes), hephaestin (in the intestine, placenta, heart, brain and pancreatic β-cells), and zyklopen (in placenta) assist the export of iron by ferroportin by oxidizing Fe(II) to Fe(III), thereby allowing it to be loaded onto transferrin 49 . There are, however, other possible mechanisms for cellular export of complexed iron. These mechanisms include the secretion of iron-containing ferritin by hepatocytes 50 , macrophages and kidney proximal tubule cells 51 , which is probably mediated by autophagy of cytoplasmic ferritin and subsequent release via the secretory-lysosomal pathway 51, 52 . Figure 1 | Systemic iron metabolism. Dietary iron is absorbed by duodenal enterocytes and added to the systemic iron pool upon export via ferroportin (FPN). Iron in the systemic iron pool, which under normal steady-state conditions is mainly bound to transferrin, is primarily utilized for erythropoiesis. Excess systemic iron is stored as ferritin in the liver and, to a lesser extent, in other tissues. The iron utilized in senescent erythrocytes is recycled by macrophages and released, via FPN, back into the systemic iron pool. FPN expression and, consequently, systemic iron availability are inhibited by hepcidin, a peptide primarily produced by the liver. In turn, transcription of the gene encoding hepcidin, HAMP, is stimulated by the presence of iron and inhibited by erythropoietic demand. 
HAMP
Another pathway is the secretion of haem by FLVCR1B, which may function as both an 'emergency valve' to prevent haem overload, especially in erythroid cells, and as a potential route for macrophages to directly supply haem to developing erythroblasts 53 .
Iron and the pathophysiology of disease Iron overload, iron deficiency and anaemia of inflammation and chronic disease. Iron overload is a major clinical challenge in the management of hereditary haemochromatosis and haemoglobinopathy-related anaemia (iron-loading anaemia). Primary iron overload, such as occurs in patients with hereditary haemochromatosis, is directly caused by disordered iron metabolism that is associated with genetic mutations in regulatory proteins. By contrast, secondary iron overload in patients with iron-loading anaemia is not intrinsically related to iron metabolism, but rather results from the anaemia that stimulates erythropoiesis and iron absorption. Moreover, the iron overload that occurs in severely anaemic patients is further aggravated by regular blood transfusions that aim to improve haemoglobin levels. Tissues commonly affected by iron overload include the liver, spleen, heart, pancreas and pituitary gland, and excess iron often eventually leads to complications such as liver failure, myocardial disease, diabetes mellitus and other metabolic disorders 54 . Iron deficiency occurs when the systemic demand for iron surpasses its supply. As erythropoiesis is, in terms of iron requirements, the most important physiological process, iron deficiency will typically present as irondeficiency anaemia. Increasing or supplementing the dietary iron intake corrects iron deficiency in most cases. However, in a rare inherited form of anaemia known as iron-refractory iron deficiency anaemia, mutations in transmembrane protease serine 6 (TMPRSS6) lead to inappropriately high hepcidin expression and restricted intestinal iron absorption; thus, intravenous iron administration is often required 55 . A high hepcidin level is also one of the hallmarks in anaemia of inflammation and chronic disease (AI/ACD). Under conditions of chronic inflammation, such as inflammatory diseases and cancer, increased expression of interleukin-6 (IL-6) and structurally related cytokines lead to the activation of the IL-6 receptor pathway, resulting in signal transducer and activator of transcription 3 (STAT3)-mediated hepcidin expression and, consequently, limited iron absorption and availability 56 . Additionally, activin B, a member of the transforming growth factor-β (TGFβ) superfamily that is expressed in the liver under inflammatory conditions, was shown to induce HAMP transcription via the signalling pathway involving SMAD1, SMAD5 or SMAD8 (REF. 57 ). Although the expression of hepcidin can be considered a useful defence mechanism against infections, as it limits the availability of iron to invading pathogens, the presence of AI/ACD in patients with chronic diseases is a common and substantial clinical problem that can negatively affect the recovery and quality of life in these patients 58 .
Iron and cellular redox status. The mitochondrial generation of ATP is highly dependent on the formation and presence of ROS, and mitochondria are a major source of cellular ROS. Mitochondrial iron homeostasis is therefore of crucial importance in the control of cellular redox and potential oxidative damage. For example, in Friedreich ataxia, a genetic disorder affecting the expression of the mitochondrial iron-chaperone frataxin, cardio myopathy is a major complication that has been associated with mitochondrial iron overload. In addition, complications secondary to hereditary haemochromatosis, including liver and cardiac toxicity, have been related to ROS-mediated damage and mitochondrial pathology 59 . Ferroptosis is a recently described form of controlled non-apoptotic cell death that heavily depends on iron and ROS 60 . Ferroptosis has been associated with a diverse range of pathologies, including neurological disorders 61, 62 , ischaemia-reperfusion injury 63, 64 and cancer 65, 66 . Although the ferroptotic pathway and its function still have several unknown features, peroxidation of lipids by cytosolic ferrous iron has a central role. Ferroptosis can be induced by blocking the system X c − cystine/glutamate antiporter, which limits glutathione production and thus reduces oxidative protection by HJV is stabilized by neogenin and cleaved by matriptase 2 (MT2), enabling the fine-tuning of BMP6 signalling. SMAD signalling is additionally regulated by transferrin receptor 2 (TFR2) upon association with human haemochromatosis protein (HFE) and HJV. HFE also interacts with TFR1 to compete with holotransferrin. Consequently, when iron supply is high, HFE is displaced from TFR1 allowing it to associate with TFR2, thereby increasing hepcidin expression via SMAD signalling. Under inflammatory conditions, interleukin-6 (IL-6) and related cytokines bind to the IL-6 receptor, resulting in Janus kinase 1 or 2-signal transducer and activator of transcription (JAK1/2-STAT3) activation and hepcidin expression to restrict iron availability. Finally, developing erythroid cells confer their iron requirements by secreting erythroferrone (ERFE), which inhibits hepcidin expression, via a currently unknown receptor and signalling pathway, to stimulate iron uptake under circumstances of high erythropoietic demand. glutathione peroxidase 4 (REF. 67 ), whereas chelation of iron protects cells from ferroptosis 60 . The interplay between mitochondrial iron, ROS and ferroptosis has recently been reviewed in depth [68] [69] [70] , and this process will undoubtedly become a source of key therapeutic targets that can be exploited to design novel therapies for diseases associated with abnormal ferroptotic activity.
Iron and immunity.
The relationship between iron and the immune system is well established. As part of the innate immune system, macrophages are highly efficient phagocytes that fulfil a central role in the first-line defence against microorganisms. In parallel, macrophages are responsible for iron recycling from red blood cells, and are thereby solely accountable for >95% of the iron supply needed for steady-state erythropoiesis. In addition, macrophages have an iron-independent growth-supporting function in erythroid development 71, 72 . Although these macrophage activities appear to be relatively dissimilar, a connection between iron status and macrophage phenotype has been firmly demonstrated. First, multiple reports have shown that high intracellular iron levels stimulate the secretion of inflammatory cytokines such as tumour necrosis factor (TNF) by macrophages 73, 74 ; the clinical significance of this phenomenon has been illustrated by several preclinical studies. For example, intravenous administration of ferumoxytol iron oxide nanoparticles (also known as Feraheme; AMAG Pharmaceuticals) significantly reduced tumour growth and suppressed liver metastasis in tumour-bearing mice 75 . Feraheme was also associated with a pro-inflammatory phenotype in tumour-associated macrophages 75 . Feraheme is an iron replacement therapy approved by the US Food and Drug Administration (FDA) for chronic kidney disease
. In another example, iron-overloaded macrophages in chronic venous ulcers have a strong pro-inflammatory phenotype, producing TNF and ROS, thereby delaying wound healing and promoting further tissue damage 76 . Finally, unbound haem and iron can induce a switch in the phenotype of macrophages from growth-supporting to inflammatory, which can be prevented by iron chelation or scavenging of haem by haemopexin 77 . Because various complications in patients with iron-loading anaemias have a chronic inflammatory component, such as liver fibrosis, leg ulcers, pulmonary hypertension and musculoskeletal inflammation, it is tempting to hypothesize that iron-mediated inflammatory activation of macrophages has a role in the pathogenesis of these complications 5 .
Iron homeostasis also influences adaptive immunity. For example, a form of immunodeficiency characterized by impaired development and function of lymphocytes has been attributed to mutations in the gene encoding TFR1 (TFRC), which affects internalization of the surface receptor 78 . Although iron deficiency is the underlying cause of this disorder, illustrated by gp, glycoprotein; JAK, Janus kinase; MHC, major histocompatibility complex; STAT3, signal transducer and activator of transcription 3; TGFβ, transforming growth factor-β; TNF, tumour necrosis factor. Haemoglobin associates with haptoglobin to allow endocytosis by the scavenger receptor CD163, after which haemoglobin is degraded and haem is transported into the cytosol. Systemic haem is scavenged by complexation with haemopexin and endocytosis via pro-low-density lipoprotein receptor-related protein 1 (LRP1). Haem can be directly transported, also from the endosome, into the cytosol by haem-responsive gene 1 protein homologue (HRG1) and feline leukaemia virus subgroup C receptor-related protein 2 (FLVCR2), where it is processed by haem oxygenase 1 (HO1) and iron is released as Fe(II). Scavenger receptor class A member 5 (SCARA5) internalizes ferritin that consists of light chains, after which iron is liberated and transported to the cytosol. Ferritin composed of heavy chains can be endocytosed by TFR1 (not depicted here). During iron utilization, the labile iron pool (LIP) comprises cytosolic Fe(II), which can be stored in cytoplasmic ferritin or utilized for biochemical processes. Most of these processes take place in the mitochondria, for which iron is supplied via mitoferrin, whereas FLVCR1B allows export of mitochondrially produced haem. The LIP controls the expression of TFR1, DMT1, ferritin and ferroportin (FPN) via the post-transcriptional iron regulatory protein-iron-responsive element (IRP-IRE) regulatory system. Similarly, the transcriptional hypoxia-inducible factor-hypoxia response element (HIF-HRE) regulatory system controls several intracellular processes, including the transcription of TFR1 and DMT1. HIF2α translation is inhibited by IRP1 (also known as cytoplasmic aconitate hydratase); conversely, IRP1 transcription is inhibited by HIF. HIF expression is regulated by prolyl-4-hydroxylase (PHD), which stimulates the degradation of HIFs under conditions of high oxygen. During iron egress, Fe(II) is exported by FPN, followed by oxidation to Fe(III) by the ferroxidases hephaestin or ceruloplasmin, and subsequent binding to transferrin. Intracellular haem can be directly exported via FLVCR1A. Note that not all pathways are present in all cells.
the reversal of defective lymphocyte proliferation by Fe(III) supplementation, interestingly, patients are only mildly anaemic. Another connection between iron and immunity is related to the defence against invading pathogens. Microorganisms, as for all other forms of life, are highly dependent on the presence of iron to support growth and proliferation 79 . Consequently, to limit infectivity of invading microorganisms, host organisms have developed strategies to restrict the iron supply to pathogens. NTBI is considered to be an important source of iron for microorganisms; indeed, some microorganisms sequester iron by releasing iron-binding proteins known as siderophores. Capture of these siderophores, as well as NTBI, by macrophage-produced lipocalin 2 is therefore an effective defensive response to infection 80, 81 . Another host mechanism to limit NTBI availability under inflammatory conditions is to block cellular iron egress by reducing ferroportin expression 82 . This inflammation-induced reduction of ferroportin is primarily driven by the upregulation of hepcidin transcription via IL-6 receptoractivated Janus kinase (JAK)-STAT3 signalling (FIG. 2;  TABLE 1 ) and via TGFβ1−TGFβ1 receptor-mediated activation of SMAD signalling, which is distinct from bone morphogenetic protein 6 (BMP6)-induced SMAD signalling 83 . Alternatively, ferroportin reduction is also controlled by hepcidin-independent mechanisms, such as signalling via Toll-like receptor 2 (TLR2) and TLR6, enabling a rapid systemic response under inflammatory conditions 84 .
Iron and cancer. Changes in cellular redox status have a considerable role in malignant transformation and metastasis of cancer cells 85 . Consequently, many researchers have proposed and investigated the potential relationship between malignancies and iron 86, 87 . Although several studies have indeed shown a correlation between the incidence and mortality of cancer and systemic iron levels, as measured by transferrin saturation or serum ferritin, this correlation is generally weak, has shown conflicting outcomes and is often confounded by the presence of other pathology 88, 89 . There is, however, clear evidence to indicate that deregulated iron homeostasis on a local -that is, microenvironmental and/or cellular -level is associated with tumour progression. This phenomenon was illustrated by changes in the expression of iron-related genes in cancer cells (FIG. 4) , the levels of which are inversely correlated with patient survival [90] [91] [92] . In the context of tumour progression, one can envision that proliferating cancer cells, which require substantial amounts of iron to support their growth, will attempt to increase their iron intake, for example, by increasing the expression of TFR1 and STEAP3 (REFS 96, 97) . Proliferating cancer cells can also increase iron availability by modulating iron storage capacity by producing ferritin 94, 96 and by limiting their iron export by downregulating ferroportin 91, [98] [99] [100] . However, the additional intracellular oxidative stress that is accompanied by the increased presence of labile iron may also make cancer cells more sensitive to ferroptosis 65, 67 and hinder tumour metastasis 85 . These results therefore illustrate the complex relationship among iron, ROS and cancer cell survival. Furthermore, although a connection between iron and cancer growth has been demonstrated in several forms of cancers, with breast cancer 90, 91, [99] [100] [101] , prostate cancer 98, 102, 103 and glioblastoma 94, 104 as established examples, it seems reasonable that many, but not all, cancer types will demonstrate a similar iron dependency.
Iron and neurodegenerative diseases. Iron homeostasis in the central nervous system (CNS) differs from that in other tissues 105 . Endothelial cells of the blood−brain barrier modulate iron influx into the CNS by importing iron from the systemic circulation via TFR1 and DMT1, and subsequently releasing iron via ferroportin at the basal side into the brain interstitium 106, 107 . This control mechanism is reminiscent to that of the absorption of iron in the duodenum. The presence of an additional layer of homeostatic regulation suggests that the brain may be spared from excessive iron accumulation in ironoverloaded patients, which is supported by the fact that large iron deposits in the brain are not typically found in patients with haemochromatosis 108 . Nevertheless, genetic mutations associated with an inherited form of haemochromatosis are over-represented in patients with Parkinson disease, parkinsonism and amyotrophic lateral sclerosis (ALS) 109, 110 , indicating that cellular, rather than systemic, disturbances in brain iron homeostasis may have a role in the pathogenesis in these diseases.
Although progressive neurological disorders have been linked to disturbances in other metals such as copper (a hallmark of Wilson disease, but also found in Alzheimer disease 111 ) and zinc (for example, in Parkinson disease 112 ), many studies have implicated cellular iron overload and iron-induced oxidative stress in the development of Parkinson disease, ALS, Alzheimer disease, Huntington disease, multiple sclerosis and several other neurodegenerative diseases 113, 114 (FIG. 4) . As an interesting example, prion protein (PrP C ) can promote the reduction of Fe(III) to Fe(II), enabling its uptake into cells by ZIP14 and DMT1 (REFS 33, 34) . However, the conversion of PrP C to its isoform PrP Sc , which is implicated in neurological prion diseases such as Creutzfeldt−Jakob disease, is promoted by unbound iron 115 , and PrP Sc can bind to ferritin to form an insoluble complex. This process stimulates the cellular intake of iron and promotes the formation of additional PrP
Astrocytes -glial cells in the CNS involved in the control of nutrient supply and brain remodelling -are thought to fulfil, in concert with endothelial cells of the blood−brain barrier, a critical role in regulating iron homeostasis in the brain 106, 117 . Astrocytes produce hepcidin in response to inflammatory signalling and intracellular iron 118 , suggesting a control mechanism via ferroportin that is similar to the regulation of systemic iron levels by hepa tocytes. This regulatory feedback loop facilitates local control over iron trafficking within the CNS, although the abundance of hepcidin in the brain interstitium suggests that at least some fraction of it is of systemic (probably hepatic) origin 119 . Low levels of ferroportin have been found in brains of patients with Alzheimer disease 120 , as well as in rat models of Parkinson disease 121 and ALS
122
. 
• In a mouse model of multiple sclerosis, reduced expression of ferroportin and intracellular iron overload were specifically found in macrophage-like microglia, but not in astrocytes 123 . Moreover, iron-overloaded microglia can be found in active multiple sclerosis lesions and have a pro-inflammatory phenotype that inhibits CNS repair, thus contributing to disease progression 124, 125 . Neurological dysfunctions are also found in patients with aceruloplasminaemia: these individuals lack functional ceruloplasmin, a protein that facilitates iron removal from tissues by oxidizing exported Fe(II) to Fe(III), thereby promoting its association with transferrin. This genetic disease is characterized by a loss of neurons, particularly in the basal ganglia, and by astrocytes with an attenuated iron efflux capacity and iron overload 126 . Finally, in a clinical prospective study, higher ferritin levels in the cerebrospinal fluid were correlated with a lower cognitive function and brain structural changes in patients with Alzheimer disease, but this correlation seemed to also be present in individuals who were considered to be cognitively normal 127 . Interestingly, genetic mutations that affect the ferritin light chain, which probably makes the iron-storage protein 'leaky', lead to a heterogeneous neurological clinical presentation known as neuroferritinopathy 114, 128 . This finding raises the question of whether dysfunctional ferritin or malfunctions in its cellular processing may have some involvement in the pathogenesis of other neurodegenerative diseases 129 .
Iron and atherosclerosis.
In atherosclerotic plaques, iron is present at much higher concentrations than in healthy tissues 130 (FIG. 4) . The function of these iron deposits in atherosclerosis, and whether iron accumulation has a causative role or is a mere consequence of the pathogenic process -for example, resulting from haemolysis -is still under debate. It seems reasonable to suggest that iron is directly involved in atherosclerosis development by catalysing the formation of oxidized low-density lipoprotein (LDL) in the arterial wall 131 , which is considered to be one of the hallmarks of atherosclerosis. However, in iron-overloaded patients with type 1 haemochromatosis, the incidence of atherosclerosis is actually lower, rather than higher, than it is in the rest of the population 132 . Interestingly, the iron status of macrophages, which have a key role in the development and progression of atherosclerotic plaques 133, 134 , could explain this paradox, as macrophages of patients with this form of haemochromatosis contain less iron than do those of healthy individuals. Conversely, patients with β-thalassaemia, a disorder that is accompanied by iron loading, particularly of macrophages, indeed do have a higher risk of developing atherosclerosis, confirming the so-called iron hypothesis in atherosclerosis 135, 136 . A relationship among macrophages, iron and atherosclerosis could partially be due to the direct role of iron in the oxidation of LDL by macrophages, as well as a phenotypic change in macrophages due to iron sequestration as described above. Nevertheless, various experimental studies that have investigated intracellular iron accumulation in macrophages as a driving mechanism for atherosclerosis have produced conflicting results. Thus, iron is considered to take part in a complex network involving several underlying mechanisms [137] [138] [139] [140] [141] .
Iron and other ageing-associated diseases. In addition to cancer, neurodegenerative disorders and atherosclerosis, various other pathologies have been linked to iron homeostasis. In diseases such as type 2 diabetes mellitus 142 , osteoporosis 143 , osteoarthritis 144 , macular degeneration 145 and liver fibrosis 146 , high levels of iron have been associated with disease severity, suggesting a possible role in pathogenesis or disease progression. Importantly, many of these disorders are considered to be chronic ageing-associated diseases of multifactorial aetiology, and are substantial causes of mortality and morbidity in the ageing Western society. These findings highlight the need for a thorough exploration of the role of iron dyshomeostasis in these diseases, as well the utility of targeting iron metabolism as a therapeutic approach or as a strategy to deliver pharmaceutical agents.
Iron metabolism as a therapeutic target Therapeutics targeting systemic iron availability.
The use of iron-chelating agents is a straightforward approach for limiting and redistributing systemic iron; therefore, these agents are frequently used in the clinical management of primary or secondary iron overload. The currently available chelators are deferoxamine (Desferal; Novartis), deferiprone (Ferriprox; ApoPharma) and deferasirox (Exjade/Jadenu; Novartis). More than 50 years ago, deferoxamine (also known as desferrioxamine B) was the first chelator that showed clinical promise 147 . Iron chelation therapy was then rapidly demonstrated to be an effective strategy for mobilizing and removing iron
Box 1 | Iron oxide nanoparticles
Over the past few years, an enormous variety of iron oxide nanoparticles have been developed for diagnostic and therapeutic applications, although few have reached the clinic and several have been withdrawn for various reasons 251 . Also known as superparamagnetic iron oxide nanoparticles (SPIONs), these sterically stabilized particles typically contain magnetite (Fe 3 O 4 ) and maghemite (γFe 2 O 3 ). The resulting magnetic properties of these SPIONs make them particularly interesting as contrast agents for magnetic resonance imaging (MRI). Owing to their nanosized dimensions, SPIONs primarily localize in phagocytic cells, mostly macrophages 252 , and in the liver, spleen and lymphatic tissues; thus, SPIONs can be utilized for imaging these tissues. For example, ferumoxytol (Feraheme; AMAG Pharmaceuticals), which is clinically approved for iron replacement therapy in chronic kidney disease, has been investigated as a marker for the presence of macrophages in solid tumours 253 . Ferumoxytol has also recently been shown to modulate the activity of these macrophages towards a pro-inflammatory, antitumoural phenotype 75 . Several additional promising applications of SPIONs include using their magnetic properties and localization to tumours to create local hyperthermia by applying an alternating magnetic field (for example, NanoTherm; MagForce) or using them as drug carriers that release their payload as a result of magnetically induced heating 254 . Although SPIONs are generally considered to be non-toxic, it is important to realize that there is no physiological route of iron excretion from the human body other than a passive intestinal loss that is typically limited to 2 mg iron per day. Therefore, intravenously administered iron oxide, which would be in the range of 400 mg iron (for example, the ferumoxytol dose used in a clinical MRI study; ClinicalTrials.gov identifier: NCT01336803) will add to the total iron pool. Thus, a pro-inflammatory phenotypic switch in the macrophages clearing these nanoparticles could be triggered 75 . Further evaluation regarding the long-term tolerability of SPIONs as routinely used imaging agents may be therefore warranted. via faecal and urinary excretion, illustrated by a marked decrease in mortality and iron-related complications in patients with thalassaemia major 148 . Despite its success, desferoxamine has poor bioavailability and requires regular (5-7 times a week) parenteral administration that is often painful and requires up to 10 hours for infusion, making patient compliance a major limitation. In the following decades, the oral iron chelators deferiprone 149 and deferasirox 150 were developed and approved for the treatment of iron overload, improving iron chelation therapy patient satisfaction compared with treatment with desferoxamine 151 . Both desferoxamine and deferasirox are currently recommended as first-line chelation therapy in iron overload, but the toxicity profile of these compounds, which includes hypersensitivity reactions, liver dysfunction, renal dysfunction and neuronal hearing loss 152 , warrants further developments in iron chelation therapies. For example, in preclinical models of iron-loading anaemia, the administration of unmodified transferrin, which can be considered the physiological iron chelator, effectively redistributed iron to developing erythroid cells 153 . In addition to iron overload disorders, iron chelation has been extensively investigated as an adjuvant therapy in other disorders. In the 1990s, clinical trials of iron chelators in patients with neuroblastoma showed antitumour efficacy 154, 155 , which encouraged further exploration of iron chelation therapy in cancer. Several novel chelating agents have been explored, one of which is currently under clinical development (DpC; Oncochel Therapeutics) 156 . In parallel, iron chelation has also shown clinical potential in neurodegenerative disorders, including multiple sclerosis 157 , Alzheimer disease 158 and Parkinson disease 159 , thereby confirming the involvement of iron in the pathogenesis of these disorders.
Since the discovery of hepcidin in the beginning of this millennium, a substantial number of agents that stimulate or block its expression or activity have been investigated (TABLE 3) . Several short hepcidin derivatives have been designed as hepcidin-mimicking agents with improved pharmacokinetic profiles, and these are currently under development by Merganser Biotech (M012, phase I) 160 , La Jolla Pharmaceutical Company (LJPC-401, phase I; see Further information) and Protagonist Therapeutics (PTG-300, preclinical; see Further information). Preclinical studies have demonstrated the beneficial activity of hepcidin derivatives in several models for red blood cell and iron overload disorders, including β-thalassaemia, polycythaemia vera and haemochromatosis 161, 162 . Interestingly, preclinical studies have also shown that a hepcidin derivative can act as an antimicrobial agent, as it limits the availability of iron to certain types of microorganisms 82 . Conversely, therapeutics that bind to and inactivate hepcidin have been developed and studied for the treatment of AI/ACD. Such hepcidin-binding agents include humanized monoclonal antibodies (LY2787106, which was discontinued after phase I trials in 2015 by Eli Lilly & Company 163 , and 12B9m by Amgen 164 ), an anticalin (PRS-080; Pieris Pharmaceuticals) 165 and an L-RNA spiegelmer (lexaptepid pegol (NOX-H94); NOXXON Pharma) 166, 167 . 123 , AD (preclinical) 255 , PD 256 and cancer (colorectal) 257 . Transferrin receptor 1 (TFR1) upregulation has been found in MS 258 , atherosclerosis 259 and cancer (colorectal cancer 257 , breast cancer 95, 101 and glioblastoma 94 ). Normal TFR1 levels have been observed in AD 260, 261 , whereas normal levels 262 and low levels have been reported 263, 264 for PD. ). Tissue iron stored as ferritin has found to be increased in MS 271 , AD 272 , PD 264 and AS 259, 273 . For cancer, both high levels (glioblastoma) 94 and low levels (breast cancer) 101 of ferritin have been reported. Similarly, microenvironmental iron deposits have been observed in MS 271 , AD 271, 272, 274 , PD 256, 264, 274 , AS 273 and cancer (colorectal) 257 . Upregulation of ferroportin (FPN) has been demonstrated in tissues of patients with PD 264 , AS 273 or cancer (colorectal 257 or breast 101 ), whereas low levels of FPN have been observed in MS (preclinical) 123 , AD 120 and in breast 91 and prostate 98 cancer. Hepcidin levels are inconsistently associated with (an inverse) FPN expression in diseases. High hepcidin concentrations have been found in MS (preclinical, tissue) 123 , AS (serum) 275 , breast cancer (tissue 91, 101 and serum 276 ) and prostate cancer (tissue) 98 , whereas low levels have been observed in the tissues of patients with AD 120 . Increased systemic ferritin concentrations have found in the cerebrospinal fluid of patients with MS 277 , AD 127 or glioblastoma 278 , as well as in the serum of patients with AS 279 or breast cancer 276 . However, the levels of serum ferritin have also been found to be normal in patients with AS 275 or non-skin cancers 280 . Systemic iron levels measured by iron concentration and transferrin saturation have been inconsistent: higher than average levels have been found in a meta-analysis in PD 281 , normal levels have been found in MS 282 and AS 275 , and low levels have been observed in AD 283, 284 . With regard to cancer, the association with systemic iron levels is unclear: women with high levels of serum iron were at higher risk for developing non-skin cancer, whereas men were at lower risk 280 .
A similar ferroportin-reducing effect can be achieved with agents that target ferroportin directly, blocking the binding of hepcidin and preventing internalization and degradation of the iron exporter protein. The structure of ferroportin has not yet been resolved, but the solved crystal structure of a bacterial homologue and modelling of human ferroportin strongly suggest that the transporter comprises 12 transmembrane domains with a central pore 168, 169 . The structural features also demonstrate similarities with the major facilitator superfamily (MFS) of transporters. The Cys326 residue that is essential for the binding of hepcidin is likely to be located inside the central pore, which could indicate that binding of hepcidin could structurally block ferroportin function before internalization has taken place 169, 170 . Fursultiamine, a small molecule also known as thiamine tetrahydrofurfuryl disulfide that targets the Cys326 residue of ferroportin, indeed reduced hepcidin-mediated internalization of ferroportin and stimulated cellular export of iron. However, the function of fursultiamine in vivo is limited owing to its rapid conversion into thiamine 171 . An antibody against ferroportin (LY2928057; Eli Lilly), which has been explored clinically, has had more success in vivo 172 . However, the largest challenge of any strategy directly targeting hepcidin or its receptor, ferroportin, is an underlying homeostatic feedback mechanism that may cause a rebound in hepcidin expression, which would abolish a large part of any long-term therapeutic effect 164 . This feedback loop may explain why the development of LY2928057 seems to have been discontinued upon completion of a phase II trial in 2015 (ClinicalTrials.gov identifier: NCT01991483).
Owing to the homeostatic control of hepcidin expression, approaches that interfere with the underlying regulatory pathways may be more useful; however, none of the agents that use such approaches has progressed past phase II of development. Several strategies inhibit hepcidin expression by modulating the BMP6-SMAD pathway. Capturing BMP6 to prevent its binding to the BMP6 receptor (BMP6R) has been clinically investigated using a humanized antibody (LY3113593; Eli Lilly) and using a fusion protein of haemojuvelin and the Fc domain of IgG (FMX-8; FerruMax Pharmaceuticals) 173 . LY3113593 was lost through attrition in 2016 (NCT02604160), whereas phase II trials of FMX-8 were terminated in 2016 owing to an inability to recruit enough patients who met the eligibility criteria. Non-anticoagulant heparinderivatives that bind to BMP6 have been investigated in preclinical studies 174 . A second strategy aims to reduce BMP6-induced hepcidin transcription downstream of the BMP6−BMP6R interaction by blocking SMAD phosphorylation using dorsomorphin 175 or its derivatives 176 . Alternatively, degradation of TFR2 mRNA via small interfering RNA (siRNA) to ultimately reduce hepcidin expression was investigated as an approach by Alnylam Pharmaceuticals 177 ; however, this therapeutic (ALN-HPN) was discontinued for unknown reasons.
A hepcidin agonistic strategy comprises inhibition of matriptase 2 (MT2)-induced cleavage of haemo juvelin. Haemojuvelin is a co-receptor in the BMP6R complex that is required for iron sensing and hepcidin induction 178 , and MT2 cleaves haemojuvelin to suppress BMP-SMADinduced hepcidin expression 179, 180 . MT2 is a type II transmembrane serine protease that is structurally similar to matriptase, an endothelial enzyme associated with tumour development. Although a crystal structure of MT2 is not yet available, modelling of the active domain has identified several residues that can be targeted, which facilitates the development of small-molecule inhibitors against MT2 (REFS 181,182) . A serum-stabilized antisense DNA (IONIS-TMPRSS6-LRx; Ionis Pharmaceuticals 183, 184 ) and a liposomal siRNA (ALN-TMP; Alnylam Pharmaceuticals 185 ) were developed to block MT2 mRNA translation, and both therapeutics showed preclinical efficacy in animal models of β-thalassaemia and iron overload. In addition, several physiological protease inhibitors have demonstrated specific MT2-inhibiting activity 186 , and some of them have a Kunitz domain that could be an important lead for the further development of hepcidin-inducing peptides 187 . The IL-6-JAK1/2-STAT3 pathway is a second regulatory pathway that induces hepcidin expression. The isoflavone genistein promotes the phosphorylation of STAT3, in addition to SMAD4, and was shown to induce hepcidin expression in zebrafish 188 . However, the activity of genistein in a preclinical or clinical setting needs to be evaluated. Conversely, inhibition of JAK by kinase inhibitors effectively reduces hepcidin expression in vitro (1,2,3,4,5,6-hexabromocyclohexane 189 ) and in vivo (AG 490 (REF. 190 )), and similar effects have been obtained by disrupting STAT3 dimerization using a STAT3-binding peptide 191 .
Therapeutics targeting cellular iron trafficking. For many diseases, disordered iron metabolism typically occurs only on a cellular level, whereas systemic iron homeostasis seems to be unaffected. Therapies that target cellular iron uptake, storage or efflux may therefore be particularly promising in these diseases. Several compounds have been developed that target the cellular uptake of iron, and DMT1 in particular has been a frequent target in preclinical studies. Structural modelling of human DMT1 (REFS 192, 193) , as well as the crystal structure of ScaDMT, a prokaryotic DMT1 homologue found in Staphylococcus capitis 194 , suggest that DMT1 is a 12-transmembrane-domain protein of two-fold symmetry and contains a hydrophobic core that coordinates the coupled transfer of a bivalent metal ion and a proton into the cytoplasm.
Several small-molecule inhibitors of DMT1-mediated iron transport have been investigated. Ferristatin restricts the cellular intake of free iron in vitro; however, its efficacy in vivo has not yet been evaluated 195 . Although the inhibitory effect of ferristatin was at first attributed to TFR1 degradation 196 , subsequent work demonstrated that ferristatin directly inhibited DMT1 activity 195 . Similarly, ferristatin II (also known as direct black 38 or chlorazol black) is a structurally unrelated compound that has shown potent TFR1-inhibiting properties, mediated via DMT1 internalization, in vitro and in vivo 197, 198 . Interestingly, ferristatin II also induces 200 , thereby limiting its translation for therapeutic purposes. The selenium-containing drug ebselen, which has an antioxidant activity similar to that of glutathione peroxidase, strongly inhibits DMT1-mediated uptake of iron (half-maximal inhibitory concentration (IC 50 ) of 0.2 μM) 201 . Thus, ebselen could have therapeutic potential in treating iron-related oxidative stress in a range of disorders; indeed, ebselen has been evaluated preclinically for iron-induced cardiomyopathy 202 . Comparably potent DMT1 inhibition was achieved with pyrrolidine dithiobarbamate (IC 50 ≈ 1.5 μM) and Δ 9 -tetrahydrocannabinol, which also have antioxidant activity 201 . Recent screening studies have identified a series of pyrazole derivatives and benzylisothioureas as potent inhibitors of DMT1 both in vitro (IC 50 < 1 μM) and in vivo (30-85% inhibition with an oral dose of 50 mg per kg) [203] [204] [205] . A particularly interesting, but not yet explored, strategy to limit iron overload may be the oral administration of a nonbioavailable DMT1 inhibitor: that is, a compound that is not systemically absorbed and therefore has limited or no systemic off-target effects but would inhibit the absorption of iron from the intestine. A potential limitation of this approach is the capacity of the intestine to absorb haem-bound iron 206 and nanosized particulate iron (such as the ferritin core) 207 , which bypass the DMT1 absorption pathway via unknown mechanisms. However, combining intestinal DMT1 inhibition with dietary restrictions could be a relatively safe therapeutic option in the treatment of primary or secondary iron overload.
The central role of ZIP14 in transporting NTBI into tissues that are typically affected by iron overload, especially the liver and pancreas 29 , makes the inhibition of ZIP14 an appealing strategy for the clinical management of iron overload. Similarly to other members of the ZIP transporter family, ZIP14 is predicted to comprise eight transmembrane domains, which are all involved in the transport of bivalent metals 208 . Whether ZIP14 is a sufficiently druggable target still needs to be evaluated.
The hypoxia-inducible factor (HIF) transcription factors, which are composed of a heterodimerized α-and β-subunit, may be another highly attractive target for interfering with iron metabolism 209 . Through binding to a hypoxia response element (HRE) in the promoter of a target gene, HIFs modulate the expression of a wide range of proteins that are involved in cellular oxygen status, glucose metabolism, angiogenesis and erythropoiesis. In parallel, the promoters of several genes encoding key iron trafficking proteins (namely, DMT1 (REFS 210, 211) , DCYTB 211 , TFR1 (REF. 212 ) and ferroportin 213 ), especially those with roles in intestinal cells, also contain such HREs and have been shown to be susceptible to HIF regulation. Consequently, inhibitors of HIFs -for example, those that bind within the carboxy-terminal PAS domains of HIF2α to prevent HIF2 heterodimerization 214 -may form an appealing strategy for limiting iron absorption and iron overload 215 . The oxygen-sensitive prolyl-4-hydroxylases (PHDs) are physiological intracellular inhibitors that regulate the post-translational expression of HIFs by promoting the hydroxylation of two proline residues in its α-subunit, labelling it for recognition by the von Hippel-Lindau (VHL)-E3 ubiquitin ligase complex and subsequent degradation 216, 217 . PHD2, which seems to be the most dominant of the three PHDs with respect to HIF regulation, is a homotrimeric protein that contains a coordinated Fe(II) and a hydrophobic pocket at its active site, and requires 2-oxoglutarate as a co-substrate 218 . By using 2-oxoglutarate analogues as competitive substrates to pharmacologically inhibit PHDs, it is possible to stabilize HIF expression, which is a promising strategy for promoting erythropoiesis in patients with anaemia 219 . Although the direct effect of HIF stabilization on the expression of erythropoietin is a key characteristic of this strategy, PHD inhibition also improves duodenal iron adsorption and utilization, as illustrated by an improved mean corpuscular volume and mean corpuscular haemoglobin of erythrocytes in a rat model of AI/ACD 220 . Moreover, increasing HIF1 expression by inhibiting PHD2 improved neuronal survival in models of Parkinson disease. This result is likely to be due to an increased expression of the lysosomal proton pump ATP13A2, which reduced the cytosolic iron pool by improving lysosomal iron storage conditions 221 . A substantial number of pharmaceutical companies, as well as one tobacco company, are actively pursuing the development of such inhibitors for the treatment of anaemia in chronic kidney disease and end-stage renal disease. Promising candidates that have already entered phase III trials include FG-4592 (also known as roxadustat; Fibrogen, Astellas Pharma, AstraZeneca Drug targeting strategies exploiting iron metabolism. Iron and iron-based materials have been widely researched for drug targeting and diagnostic applications. Iron oxide nanoparticles have received particular attention owing to their superparamagnetic properties, which can be harnessed for therapeutic and diagnostic purposes
. The metabolism of iron can be utilized for the delivery of therapeutics to specific sites in the body by targeting iron-related proteins that are upregulated in certain tissues and pathological processes (FIG. 5) . Targeting TFR1 using drugs and drug delivery systems functionalized with transferrin, antibodies, antibodyderivatives or TFR-targeted peptides is a commonly used and arguably the best-known strategy, as illustrated by its usage as a prototypical system for mechanistic studies of active targeting to cancer cells 228 . An impressive number of different TFR-targeted delivery systems have been designed and evaluated for cancer therapy by exploiting the increased expression of TFR in some tumours, and this strategy has shown preclinical benefit when using a low-dose regimen 229 . At least three TFRtargeted systems are currently under clinical development (TABLE 3) : MBP-426 (Mebiopharm), SGT-53 and SGT-94 (SynerGene Therapeutics) 230, 231 . An elegant strategy that has been evaluated in preclinical cancer models is the application of transferrin-artemisinin conjugates as cytotoxic agents 232 . Artemisinin, discovered and developed by Tu Youyou, for which she was awarded the 2015 Nobel Prize in Physiology or Medicine, is a drug with antimalarial activity. Artemisinin is isolated from the herb Artemisia annua and contains an intramolecular peroxide bridge. Fe(II) is involved in the activation of artemisinin by cleavage of this endoperoxide bridge, resulting in the formation of reactive carbon-centred radicals and . By using transferrin as a targeting moiety, both iron and the inactive artemisinin can be delivered to TFR-overexpressing cancer cells; upon internalization of the complex, the released Fe(III) is reduced to Fe(II), which in turn activates artemisinin into its cytotoxic form 232 . However, the effect of such artemisinin-based constructs on other tissues with high TFR1 expression, notably the bone marrow, has not yet been reported. A second notable application of TFRtargeting therapeutics is the transport of drugs and drug delivery systems across the blood−brain barrier. The endothelial cells of the blood−brain barrier transcytose transferrin-TFR complexes to the brain parenchyma to fulfil the iron requirements of the CNS. Exploiting this mechanism, transferrin and antibodies that target TFRs can be used as a Trojan horse to deliver drug carriers and macromolecules to the brain; however, future evaluation should demonstrate its practical potential in a clinical setting 234, 235 .
Ferritin is a commonly used biomolecule for drug targeting because it can efficiently encapsulate large amounts of drugs owing to its 'nanocage' structure 236 . Ferritin can also function as a ligand to target cells that express high levels of ferritin-internalizing receptors, such as SCARA5 and TFR1 (REF. 237 ). Moreover, ferritin disassembles at a low pH and reassembles at physiological pH, which facilitates drug loading and endows the protein with pH-triggered drug release properties, enabling discharge specifically upon uptake and lysosomal processing by the target cell 238 . A relatively specific approach to target a subset of macrophages is the use of haemoglobin clearance mechanisms. The haemoglobin-scavenger receptor CD163 is exclusively expressed by macrophages and monocytes that recycle iron 35 . CD163 can also be found in, for example, solid tumours 239 and inflamed tissues 240 , as these tissues have increased iron requirements. Consequently, a liposomal targeting strategy exploiting tissue-specific expression of CD163 using a CD163-specific antibody demonstrated effective macrophage targeting in vivo compared with untargeted nanocarriers 241 . The value of haem as a targeting ligand, which uses differences in cellular affinity for haem to specifically target subsets of cells, has not yet been fully explored. In vitro studies have shown that poly(lactic-co-glycolic) acid nanoparticles functionalized with haematin, the oxidized Fe(III) form of haem, localize in tumour cells 242 . Moreover, haem targeting improves the uptake of oligonucleotides in hepatocytes 243 ; thus, further evaluation of haem targeting is certainly warranted.
Merits and challenges of targeting iron metabolism as a therapeutic strategy. The majority of therapeutics that target iron metabolism have been developed in the context of haematological diseases and iron homeostasis disorders, such as iron deficiency and overload. However, rapidly accumulating evidence implicates iron in a variety of other (often ageing-related) disorders, such as neurodegenerative diseases and atherosclerosis. Thus, further exploration of these therapeutic agents and their targets in other pathologies is certainly warranted. Of note, unbalanced iron trafficking should not be considered the sole cause of a disease. However, the chronic and inflammatory character of the underlying pathological processes in iron metabolism-related diseases suggests that an iron-induced change in redox state within the affected tissues may form the missing link in the pathogenesis of several multifactorial disorders 86, 105, 244 . Importantly, apart from directly modulating the function of cells responsible for the condition, such as neurons and tumour cells, iron also affects the inflammatory activity of local immune cells, especially macrophages 134, 245, 246 
. Consequently, interfering with iron metabolism may be a promising therapeutic strategy in these disorders for which there are currently few effective treatments available. A clear additional advantage of such an approach is that interfering with iron metabolism typically addresses pathological pathways that are complementary to those targeted by other therapeutic approaches. Thus, additive or possibly even The natural ligand and the merits of its use as a delivery strategy are presented for each target. Transferrin receptor 1 (TFR1), CD163 and scavenger receptor class A member 5 (SCARA5) facilitate the endocytosis of drugs associated with their natural ligands. Subsequent lysosomal processing would then liberate the targeted drug, which then enters the cytosol by passive diffusion from the lysosome. This process is also likely to occur for haem-targeted constructs upon internalization by pro-low-density lipoprotein receptor-related protein 1 (LRP1). The direct transport of the haem-linked drug into the cytosol by haem-responsive gene 1 protein homologue (HRG1) and/or feline leukaemia virus subgroup C receptor-related protein 2 (FLVCR2) could represent an alternative mechanism of drug uptake into the cytosol. Drug targeting to ferroportin (FPN) has not yet been explored, but forms an interesting approach for directing therapeutics to cells that overexpress FPN, such as some types of tumour cells. synergistic effects could be achieved when a therapy that targets iron metabolism is used in a combination strategy.
However, the broad involvement of iron metabolism in many relatively diverse physiological and pathological processes potentially make iron modulation as a therapeutic strategy a double-edged sword. Although irontargeted therapeutic interventions may effectively change the iron status in diseased tissues to treat a disorder, they also have an inherent risk of perturbing systemic iron homeostasis that may lead to substantial side effects, such as erythropoietic disorders. Using a targeted strategy that enables the delivery of therapeutics to specific tissues could limit such off-target activity.
In addition, most iron metabolism-related disorders are associated with cellular iron accumulation, which, owing to the late onset of symptoms, is most likely a chronic process that takes several years to establish. Interfering with this process once iron-induced cellular damage has already occurred may not have a direct therapeutic effect, and prevention may be more efficacious in this context. Nevertheless, limiting further deterioration and modulating the inflammatory state within the affected tissue could certainly make iron metabolismtargeted therapies an effective adjuvant treatment 124, 247 .
Conclusion and outlook
Over the past decade, a multitude of iron metabolism-targeting agents have been developed and clinically evaluated in diseases with an obvious iron-related background, such as anaemia, iron overload and ironloading anaemia. However, alterations in iron metabolism are also observed in a wide range of disorders, including cancer, neurodegeneration, atherosclerosis, type 2 diabetes, osteoporosis, osteoarthritis, retinal disorders and liver fibrosis.
The chronic inflammatory and ageing-related character of many of these conditions suggests that a slowly changing intracellular iron level, causing a shift in cellular redox status that eventually may result in cellular damage, is an underlying mechanism that could be exploited for the development of new therapeutic approaches. Further investigation is therefore required to explore current and newly developed therapies that target iron metabolism in a much broader context than haematological pathologies alone.
Modulation of macrophage activity by targeting their role in iron recycling may be a particularly interesting approach. Similar to iron metabolism, the role of an altered macrophage phenotype has been increasingly implicated in various disorders 248 , and both concepts seem to be interconnected 245 . Targeted approaches -for example, those using nanosized drug delivery systems that preferentially accumulate in phagocytic cells to specifically interfere with iron trafficking in macrophages -would thereby enable therapeutic modulation of macrophage activity in cancer and chronic inflammatory disorders 75, 249, 250 . To achieve this goal, the cellular mechanisms governing the relationship between macrophage phenotype and its iron load need to be further elucidated. For example, recent work has demonstrated that internalization of unbound haem induces an inflammatory phenotype in macrophages, whereas using haem in complex with haemopexin, which is scavenged by LRP1, does not cause such a phenotypic switch 77 . This observation indicates that the pathway of internalization, rather than the absolute load of iron, has a dominant role in the influence of iron on the phenotype of macrophages, thereby providing valuable clues for the identification of new strategies for macrophage-modulating therapies.
Overall, owing to the substantial advances in our understanding of the role of iron in a range of diseases, it has become clear that targeting iron metabolism is a compelling new therapeutic strategy for these disorders. Although further research is still required to systematically explore the value of targeting the various ironrelated proteins in individual pathologies, these efforts will almost certainly prove to be valuable in the quest for novel efficacious therapies for diseases associated with disturbed iron metabolism.
